Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

31 October 2011

Bristol-Myers Squibb, Gilead Sciences in licensing deal to produce new combination HIV pill

via The Washington Post, by Assoicated Press

Drugmaker Bristol-Myers Squibb Co. will develop a once-a-day pill to treat the HIV virus that combines its popular Reyataz with an experimental drug from Gilead Sciences Inc., the companies said Wednesday.

Under the licensing deal, Bristol-Myers will formulate, manufacture and sell the pill. It will include Reyataz, a popular drug in the class called protease inhibitors, and Gilead’s cobicistat, which is designed to boost blood levels of some HIV drugs. It works by blocking an enzyme that breaks down drugs in the body.

Gilead currently is doing mid- and late-stage human tests using the two drugs together to treat newly diagnosed HIV patients.

The two companies already have a joint venture selling the three-drug combination pill Atripla, the top-selling HIV pill in the U.S., with more than $3 billion in global sales last year. It includes Sustiva, made by Bristol-Myers, and Gilead’s Viread and Emtriva.

Read the rest.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

No comments:

Post a Comment